News
After CagriSema blow, Novo reveals data for obesity 'triple'
Novo Nordisk's triple-action obesity therapy UBT251, licensed in a $2bn deal last year, achieved almost 20% weight loss in a mid-stage trial.
News
MSD splits pharma business, hiving off oncology
MSD is separating its cancer and non-cancer pharma operations as it prepares for the looming loss of patent protection for $31bn blockbuster Keytruda.
News
FDA maps new regulatory route for ultra-rare diseases
The FDA has sketched out its 'plausible mechanism' regulatory pathway for individualised therapies that treat ultra-rare diseases.
R&D
Why the government’s latest funding push is critical to the ...
Many of the UK’s most promising life sciences innovations continue to face persistent funding challenges, made worse by an increasingly volatile globa
News
Gilead buys cell therapy partner Arcellx for up to $7.8bn
Gilead has shored up its position in cell therapies with a deal to acquire Arcellx, taking full control of their partnered multiple myeloma CAR-T.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
